Treatment with Duodopa: Its drawbacks;Tratamiento con Duodopa: Inconvenientes

Revista de Neurologia

Volumn 50, Issue SUPPL. 1, 2010, Pages

  Arbelo González, José Matías ^a  

^a HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CARBIDOPA PLUS LEVODOPA;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; DYSPHAGIA; HUMAN; HYPERSALIVATION; INFECTION; INFECTION PREVENTION; PARKINSON DISEASE; PERITONITIS; PSYCHOSIS; RISK BENEFIT ANALYSIS;

EID: 77949517629     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Nyholm D, Lewander T, Johansson A, Lewitt PA. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008; 31: 63-73.
2. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease -long-term experience. Acta Neurol Scand 2001; 104: 343-8.
3. David D; The French Duodopa Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009; 24: 993-1000.
4. Nyholm D, Aquilonius SM. Levodopa infusion therapy in Parkinson's disease. Clin Neuropharmacol 2004; 27: 245-56.